VIVE:NASDAQ

Viveve Medical Inc.

Viveve, Inc. is a women's health company committed to enhancing women's lives by providing clinically proven, high quality products that improve their overall health and well-being.

Viveve's lead product, the globally patented, non-surgical Viveve® System, is a revolutionary medical device that remodels and restores vaginal collagen using reverse-thermal gradient radiofrequency technology in a single 30-minute out-patient session. The Viveve System has regulatory approval in many countries globally and is available through physician import license in Japan.
VIVE:NASDAQ

Expert Comments:

Anthony Vendetti, Maxim Group (8/11/17)
"We believe Viveve Meeical Inc.'s Phase 3 trial is on track for a readout of data in mid-2019, and continue to be encouraged by the strong U.S. sales performance (60% of total systems sold) under its current indication. . .VIVE reported 2Q17 total revenues of $3.08M, up 97.7% y/y. . .gross margin of 40.3%, up 600bps y/y. . .management met with the FDA, and they expect to resubmit the investigational device exemption (IDE) to the FDA by early September. If the protocol is approved, the company should commence the Phase 3 trial by the end of 2017."

Jeff Cohen, Ladenburg Thalmann (8/11/17)
"We believe that Viveve Medical Inc. is currently in discussion with the agency and that a formal IDE would be submitted in the coming months such that a study (VIVEVE II) would commence in late 2017. . .the study would take approximately 12-18 months in duration and that the company would be able to commercialize under this label in 2H18 or early 2019. The study is likely to enroll approximately 250 with 20 to 25 sites. We believe that this claim would eventually prove to further open up the potential marketplace from aesthetics to also include gynecological physicians."

Brian Marckx, analyst with Zacks Small-Cap Research, reports that a $20 million loan received by a U.S.-based medical device company could further fuel growth.
read more >
Brian Marckx, Zacks Equity Research (7/11/17)
"Viveve Medical Inc. is off to a strong start, we expect domestic sales to accelerate throughout 2017. . .VIVE hopes to eventually gain FDA clearance of the Viveve System for an indication related to the improvement of sexual function. While we had hoped the pivotal study would begin this year, that timeline may now be pushed to 2018 given that FDA recently asked for additional safety related data. . .there's several reasons why we expect international sales to pick up throughout 2017 including the agreement with their distributor in China, requiring that company to purchase at least 75 units this year"

Viveve Medical's Q1/17 results beat expectations, an accomplishment that was welcomed by several industry analysts.
read more >
Gregory Chodaczek, B. Riley & Co. (5/12/17)
"Viveve Medical Inc. reported revenue of $3.04MM, $265,000 higher than we had expected. . .for the quarter, the company sold 42 Viveve Systems, 29 of which were sold in the U.S., and 2,200 disposable treatment tips. . .Viveve announced it had received an expanded indication for the Viveve system in South Korea which now includes for the treatment of vaginal laxity. . .the company has regulatory approvals in 54 countries and expects another 14 regulatory approvals by the end of the year."

Jeff Cohen, Ladenburg Thalmann (5/12/17)
"We reiterate our Buy rating for Viveve Medical Inc. and price target of $22.00 for VIVE. The company has plans for dual pathways into the U.S. marketplace of which the first has been approved. . .the second approach that the company plans to pursue would entail a clinical proven pathway (trial) for approval which would likely be for the treatment of vaginal tissue to improve sexual function. We believe that the company is currently in discussion with the agency and that a formal IDE would be submitted in the coming months such that a study (VIVEVE II) would commence in late 2017."

Anthony Vendetti, Maxim Group (5/12/17)
"We would continue to be buyers of Viveve Medical Inc. following its seventh consecutive quarter of double-digit revenue growth driven by a successful launch of the U.S. commercialization coupled with reaffirmed guidance. For the quarter, 62% of its better-than-expected sales were attributed to the U.S. market, which was commercialized in late January. . .VIVE expanded its South Korean indication to include vaginal laxity and received regulatory approval in Malaysia. . .we believe management's focus on supporting its commercialization efforts in the U.S., obtaining additional regulatory clearances, and investing in market awareness, should provide the foundation for further growth."

As Viveve Medical ramped up its U.S. sales force, reported record earnings, increased the number of countries that have given regulatory approval and saw the results of its VIVEVE I clinical study published in the Journal of Sexual Medicine, a trio of analysts took notice.
read more >

More Expert Comments

Experts Following This Company

Gregory Chodaczek, Analyst – Sterne Agee
Jeff Cohen, Analyst – Ladenburg Thalmann
Josh Jennings – Cowen & Co.
Brian Marckx, CFA – Zacks Small-Cap Research
Anthony Vendetti – Maxim Group

The information provided above is from analysts, newsletters, the company and other contributors.

Viveve Medical Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
 
First clinically efficacious technology addressing a $7B market opportunity with limited to no competition
 
Seasoned medical device executive team with a history of significant successes
 
Highly undervalued stock with >90% ownership from high quality, institutional healthcare investors